Target intelligence / Profile preview

DNA damage response (DDR) pathways (DDR)

Target
DDR
Molecular classification
Enzyme, Transcription factor, Other
01

Overview

The DNA damage response (DDR) pathways represent a sophisticated network of cellular mechanisms designed to identify and correct various forms of DNA damage, thereby preserving genomic stability (Jackson & Bartek, 2009, Nature 461:1071-1078). These pathways include base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), and double-strand break repair mechanisms like homologous recombination (HR) and non-homologous end joining (NHEJ). In many cancers, specific DDR pathways are mutated or downregulated, leading to an increased reliance on alternative repair mechanisms (O'Connor, 2015, Molecular Cell 60:547-560). This dependency provides a therapeutic window for DDR inhibitors, which can induce synthetic lethality—a state where the loss of two compensatory pathways leads to cell death, while the loss of either alone is compatible with life (Lord & Ashworth, 2012, Nature 481:287-294). Clinically, drugs like PARP inhibitors have successfully exploited these vulnerabilities in patients with BRCA mutations, and ongoing research is expanding into inhibitors of ATR, ATM, and DNA-PK to enhance the efficacy of chemotherapy and radiotherapy.

Other names
DNA repair pathwaysGenome maintenance pathwaysDNA damage response and repairDDR pathways
02

Mechanism of action

Inhibition of specific DNA repair enzymes (e.g., PARP, ATR, ATM) to prevent the repair of DNA lesions, leading to accumulated genomic damage and cell death, often through synthetic lethality in cells with existing repair deficiencies.

03

Biological functions

DNA repairCell cycle checkpoint controlApoptosisGenome stability
04

Disease associations

CancerNeurodegenerative diseaseAgingImmunodeficiency
05

Safety considerations

MyelosuppressionAnemiaNeutropeniaRisk of secondary malignancies (e.g., MDS/AML)Gastrointestinal toxicity
06

Interacting drugs

Olaparib

6 more in the full profile.

07

Biomarkers

BRCA1 mutationBRCA2 mutationHomologous recombination deficiency (HRD)Microsatellite instability (MSI)Tumor mutational burden (TMB)

Beyond the preview

Go deeper on DNA damage response (DDR) pathways (DDR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA damage response (DDR) pathways (DDR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call